Surgical site infection (SSI) after immediate breast reconstruction is much more common than would be expected after a clean surgical procedure. Although the SSI rates reported in individual studies are quite variable, there are no obvious explanations for the variation in infection rates between institutions. The microbiology of these SSIs is unusual, with higher proportions of infections caused by atypical Mycobacterium species and Gramnegative bacilli than would be expected for this anatomic site. In an effort to prevent SSIs, many surgeons use a variety of different practices including irrigation and soaking of implants with antibiotic solutions and prolonged duration of prophylactic antibiotics, although the literature to support these practices is very sparse. In particular, prolonged use of antibiotics post-discharge is concerning due to the potential for harm, including increased risk of Clostridium difficile infection, development of antibiotic-resistant organisms, and drug-related allergic reactions. With higher rates of mastectomy and breast implant reconstruction in women with early-stage breast cancer, including greater utilization of reconstruction in higher-risk individuals, the number of women suffering from infection after oncologic reconstruction will likely continue to increase. It is imperative that more research be done to identify modifiable factors associated with increased risk of infection. It is also essential that larger studies with rigorous study designs be performed to identify optimal strategies to decrease the risk of SSI in this vulnerable population.
Introduction
An estimated 247,000 women were diagnosed with in situ or invasive breast cancer in the USA in 2016, with over 90% of cases categorized as localized or regional disease [1] . In the last decade, women with in situ or locally invasive disease, who were likely eligible for breast conservation surgery, increasingly had mastectomy performed [2•, 3] . This translates into approximately 95,000 mastectomy procedures per year performed in women with breast cancer in the USA. Concomitant with increased utilization of mastectomy, the proportion of women choosing to undergo immediate or delayed breast reconstruction increased at least 1.6-fold in the USA and over twofold in England from 2005 to 2014 [4, 5, 6 •]. The increase in immediate breast reconstruction is primarily associated with increased use of prosthetic-based reconstruction [4, 7] and increased use of reconstruction in higher-risk women [8••] .
One concern with increasing use of immediate reconstruction is the potential for higher incidence of surgical site infection (SSI). Several studies have reported increased risk of SSI associated with breast reconstruction; however, reported SSI rates vary widely depending on the definition used for infection, surveillance method to identify infections, and length of follow-up after operation. Even less information is available to compare the risk of SSI after prosthetic versus autologous reconstruction. Since reconstruction is performed primarily in younger women, the impact of SSI can be longlasting, with increased hospital length of stay and hospital costs, additional surgical procedures, lower quality of life, and lower satisfaction with the surgical outcome in women with SSI compared to women without infection [9] [10] [11] .
Incidence of surgical site infection after mastectomy with and without immediate reconstruction
The majority of breast procedures are considered clean operations according to the National Healthcare Safety Network (NHSN), defined as no inflammation encountered during surgery and no exposure to mucous membranes. As such, clean operations have the lowest expected incidence of SSI, typically on the order of 1-2% in the prophylactic antibiotic era. Although this is generally true, investigators have noted that SSI rates within an individual wound class can be highly variable, depending on specific operative and patient characteristics [12] . Mastectomy without immediate reconstruction appears to fit into this category, with SSI rates reported in the past decade from individual studies higher than would be expected for a clean procedure, ranging from approximately 3-18% (Table 1) . SSI rates reported from the USA and Japan are lower (2.9-7.7%), while higher rates have been reported from limited resource countries. We speculate that the higher rate of SSI after mastectomy compared to other breast operations, such as reduction mammoplasty, may be due to the longer operative time and large dead space in which lymphatic or serous fluid can accumulate, providing a rich source of nutrients for contaminating bacteria.
As shown in Table 1 , numerous investigators have reported SSI rates after mastectomy with immediate implant reconstruction in the surgical literature. Most often, tissue expanders are used for immediate reconstruction, with subsequent second-stage reconstruction occurring 3-6 months later. More recently, some surgeons have performed direct-to-implant single-stage reconstruction without placement of a tissue expander. As shown in Table 1 , the reported SSI rates after immediate implant reconstruction vary dramatically, with some reporting rates lower than for mastectomy without reconstruction (G2%), and others reporting rates 910%. The reason for the wide variation in SSI rates is unknown, but contributing factors may be the variation in definitions used for SSI, aggressiveness of surveillance, and duration of follow-up for infection. In addition, reporting of SSI rates per breast rather than per person makes it difficult to compare many of the results, particularly when a large proportion of the procedures are bilateral operations, which have increased over time [5] .
Although the infection rates shown in Table 1 for studies that included only or primarily direct-to-implant reconstruction appear low compared to many of the studies involving tissue expander reconstruction, direct comparison of SSI rates between the two types of implant reconstruction was only performed in two studies, with differing results. Gfrerer [38•] found increased risk of SSI whereas Susarla [37] found no difference in infection rates associated with tissue expander compared to direct-to-implant reconstruction.
Many investigators have reported SSI rates after mastectomy with autologous flap reconstruction, although the majority of these studies are very small (G100 patients) resulting in unstable SSI rates. The studies summarized in Table 1 were restricted to larger series with a minimum of 100 patients. Similar to the findings with immediate implant reconstruction, the reported SSI rates range from G1 to 910%, with no clear reasons for the wide variation.
The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) data has also been used by many investigators to study 30-day SSI rates after mastectomy. Using the 2005-2012 NSQIP data, Butz compared 30-day SSI (superficial or deep incisional) rates in women who underwent mastectomy-only compared to immediate reconstruction (implant or autologous). They reported the same 2.9% SSI rate after both mastectomyonly and mastectomy plus reconstruction in younger women, and slightly higher SSI rates in women aged 65 years and older undergoing immediate reconstruction compared to mastectomy-only (3.6 versus 3.1%) [55] . Most recently, the SSI rate after mastectomy with immediate tissue expander reconstruction reported using the NSQIP database was 3.4% [56, 57] . The SSI rates after immediate autologous reconstruction in the NSQIP database vary depending on the type of flap reconstruction, ranging from 2.8% after pedicled latissimus dorsi (with or without concurrent implant), to 5.5% after microvascular free flap, and 6.0% after pedicled transverse rectus abdominis myocutaneous (TRAM) flap [57] . Silva and colleagues compared the SSI rates after immediate unilateral and bilateral implant versus autologous reconstruction using the 2005-2013 database, and found higher rates after bilateral versus unilateral surgery for both implant (3.6 versus 3.3%, respectively) and autologous reconstruction (5.2 versus 4.3%, respectively) [58] .
The SSI rates reported from the NSQIP data are clearly low compared to the majority of studies in the surgical literature, most likely due to the restricted 30-day surveillance for complications in NSQIP. In a cohort of women undergoing mastectomy with immediate implant reconstruction, we found that 48% of SSIs had onset 930 days after operation [30] . Similarly, Weichman [59] and Chidester [60] reported mean times to SSI of 31 and 35 days, respectively, after implant reconstruction. In a comprehensive analysis of infections after immediate tissue expander reconstruction over a 10-year period, Viola and colleagues found that the median time to SSI was 47 days, with only 30% of the total SSIs identified in the first 30 days after operation [44••] . In our study, which followed patients for 180 days using private insurer claims data, we found that only about one half of SSIs after immediate reconstruction were identified within 30 days [18] . In a recent study reporting results from a multicenter cohort of mastectomy reconstruction patients, 53% of SSIs after direct-toimplant and only 44% of SSIs after tissue expander reconstruction occurred within 30 days after operation [48••] . These results suggest that approximately half of SSIs are missed in studies that restrict surveillance to a short 30-day window after operation, and emphasize the importance of longer follow-up, particularly in patients with implant reconstruction.
Risk factors for SSI after breast surgery
A variety of risk factors have been identified for SSI across reconstructive approaches (including no reconstruction). Risk factors identified repeatedly in multivariate analyses using institutional data or the most recent NSQIP data include obesity or increased body mass index (BMI) [38•, 61-69, 70•, 71, 72] , larger breast size [21, 47, 66] , diabetes [32, 61, 68, 69, 72, 73] or hyperglycemia [74] , smoking [16, 42, 61, 67-69, 72, 73, 75-78] , heavy alcohol use [61, 79] , older age [16, 62, 74, 78] , higher ASA score [57, 69, 79] , history of radiotherapy [21, 42, 64, 77] , duration of operation (mastectomy-only) [16, 62, 69] , bilateral operation [21, 68] , and drain duration [47, 80] . In studies that included all operations (with and without immediate reconstruction), implant [68, 77] or autologous flap [68] reconstruction were associated with increased risk of SSI. In a meta-analysis of seven studies, Zhang found that immediate reconstruction was associated with 1.5-fold increased risk of SSI compared to mastectomy-only [81] . Additional factors associated with increased risk of SSI in studies that focused on mastectomy with immediate implant reconstruction included older age [70•] , adjuvant radiotherapy [36, 82, 83] , longer duration of operation [70•] , tissue expander compared to permanent implant [38•] , larger breast volume [83] , and higher intraoperative expander fill [83] . In two NSQIP studies, pedicled TRAM and microvascular flap were associated with increased risk of SSI compared to immediate implant [71] or latissimus dorsi pedicled flap reconstruction [72] .
In the past decade, use of acellular dermal matrix (ADM) as an inferolateral sling in tissue expander and direct-to-implant reconstruction has grown substantially, with routine use reported by 84% of plastic surgeons performing breast reconstruction in a recent survey [84] . Some purported reasons for the increased use of ADM include better pocket control, potential to perform directto-implant reconstruction (without the need for tissue expansion) [49] , and decreased risk of capsular contracture [85] , although the evidence for these benefits in the literature is relatively weak [86] .
Synthesizing the literature regarding ADM and SSI risk is difficult for a number of reasons. Some observational studies have not reported significantly increased risk of SSI associated with ADM (compared to non-use), although due to small sample sizes many of these studies lacked sufficient power to detect a significant difference [87•] . Of the studies that reported significantly increased risk of SSI associated with ADM, different reconstruction procedures were included: three studies included only tissue expander primary reconstruction [27, 88, 89] , one had only a small number of direct-to-implant reconstructions [24] , and two studies included a mixed population but controlled for increased risk of SSI associated with obesity [63] and with use of a tissue expander [38•] . In a meta-analysis of 17 studies published through 2014, ADM was associated with 1.4-fold increased risk of SSI compared to no use, although significant heterogeneity was noted between studies [90] . In an analysis of immediate tissue expander-based reconstruction from 2005 to 2011 in the NSQIP data, Winecour reported a significantly higher rate of 30-day SSI in procedures with ADM compared to no use (4.5 versus 3.2%, respectively) [70•] .
Defining the risk of SSI associated with ADM in tissue expander reconstruction is further complicated by the availability of different products, including matrices of human, bovine, or porcine origin and different degrees of sterility (i.e., terminally sterilized or non-sterile aseptic products) [87•] . Additionally, when tissue expander reconstruction is performed with ADM, a larger volume of saline is typically used for intraoperative inflation of the tissue expander, and the time to final expansion is shortened, which could confound the relationship between ADM use and risk of SSI [87•] . Definitive evidence for the safety of ADM and the risk of SSI in direct-to-implant versus tissue expander primary reconstruction likely will require randomized controlled trials to eliminate the variation in practice patterns and patient selection evident in the existing observational studies.
SSI risk prediction models
Models that can be used to predict SSI risk in women undergoing mastectomy or breast reconstruction have been developed by three groups. Kim and colleagues developed a risk model for SSI after immediate reconstruction using the 2005-2011 NSQIP data. The model contained 11 variables including age, BMI, higher ASA score, bleeding disorder, previous cardiac revascularization, diabetes, active smoking, dyspnea, hypertension, and reconstruction type, and had a c-statistic of 0.678 [71] . Kim subsequently used data self-reported by surgeons in the Tracking Operations and Outcomes for Plastic Surgeons database to develop a second immediate reconstruction SSI risk model. This model contained a smaller set of variables available preoperatively, including age, BMI, former or current smoker, diabetes, higher ASA score, and type of reconstruction, and had a c-statistic of 0.637 [57] . Kato reported a risk score for SSI after immediate or delayed tissue expander or implant reconstruction with 7 variables, including age ≥50 years, diabetes, repeated expander insertion, large expander size, neoadjuvant chemotherapy, nipple-sparing mastectomy, and postoperative hormone use, with a c-statistic of 0.734. The risk score was used to categorize risk into three strata, with progressively higher cumulative incidence rates of SSI [32] . We recently reported a risk prediction model for SSI after mastectomy with or without immediate reconstruction, which included 14 variables (rural residence, rheumatologic disease, depression, diabetes, hypertension, liver disease, obesity, pre-existing pneumonia or urinary tract infection, smoking, smoking-related diseases, bilateral mastectomy, implant or flap reconstruction, and home healthcare (with lower risk of SSI)) [68] . The c-statistic in a validation population was 0.649. In this risk model, implant and autologous flap reconstruction were both associated with about twofold increased risk of SSI, compared to mastectomy alone. We also created three risk strata based on predicted SSI risk, and found good correlation with the expected and observed infections in the strata. Further work to develop accurate models to predict SSI risk in women eligible for breast reconstruction is needed in order to provide accurate information regarding risk of complications so women can make a truly informed decision regarding immediate reconstruction. These risk prediction models will also enable discussion with the patient of her role in management of underlying conditions to minimize complications.
Microbiology of SSI after mastectomy or breast reconstruction
An interesting feature of SSI after breast reconstruction procedures is the unusual spectrum of bacteria infecting what is generally considered to be a clean surgical site. Numerous reports of SSI caused by nontuberculous Mycobacterial species exist in the literature, most often associated with implant reconstruction [20, 41, 44••, 63, 91, 92] . In addition, the proportion of Gram-negative bacilli isolated from wound cultures in women with SSI after mastectomy is much higher than would be expected from breast specimens, ranging up to 50% in some studies [13, 20, 44••, 59, 60, 77, 82, 93-96] . The presence of nontuberculous Mycobacteria and in particular antibiotic resistant Gramnegative bacilli in infected wounds complicates treatment, since empiric therapy of breast surgical wounds does not usually include antibiotics active against these bacteria. In addition, Spear found that infection with "atypical bacteria," including Gram-negative bacilli and methicillin-resistant Staphylococcus aureus (MRSA), was associated with significantly greater implant loss than infection with the more common skin flora [95] . In their comprehensive review of the microbiology of tissue expander infections, Viola found that MRSA or Pseudomonas predominated in early SSIs within 30 days after operation [44••] . Clearly, more work is needed to understand the origin of bacteria responsible for these infections and the role of biofilm in implant infections, in order to develop more effective preventive strategies and inform choice of empiric antibiotics in women presenting with infection.
SSI prevention strategies-prophylactic antibiotics
Discontinuation of prophylactic antibiotics within 24 h of surgery is recommended by numerous organizations, including the Society for Healthcare Epidemiology of America and Infectious Diseases Society of America [97, 98] . Despite this recommendation by numerous professional societies, continuation of prophylactic antibiotics post-discharge is very common in breast operations, particularly breast reconstruction. The most recent American Society of Plastic Surgeons practice guidelines for expander/implant breast reconstruction recommends that antibiotics should be discontinued within 24 h after surgery unless drains are present, in which case prophylaxis duration is left to surgeon preference [99] . In a 2009 survey of 650 plastic surgeons, 72% continued prophylactic antibiotics after discharge in women with immediate breast reconstruction, with cephalexin used in 75% of cases [100] . In a more recent survey of plastic surgeons performing breast reconstruction, 88% continued antibiotics postoperatively, with 32% discontinuing antibiotics within 5 days and 45% continuing for 6 to 10 days postoperatively [84] . These survey results are consistent with a systematic review performed by Phillips of antibiotic utilization in breast reconstruction. In their summary of antibiotic protocols reported in publications from 2005 to 2010, continuation of prophylactic antibiotics until removal of drains was most frequently reported, with prolonged utilization of antibiotics for 4-7 days postoperatively and perioperative use also common [101••] . In a retrospective review of all tissue expander reconstructions during a 10-year time period, Viola and colleagues reported use of postoperative oral prophylactic antibiotics in 78% of cases, with duration ranging from 1 week or until removal of drains [44••] .
Despite its pervasive use, there is little evidence to support the use of postdischarge prophylactic antibiotics after mastectomy. In the past decade, 10 studies have been published comparing SSI rates depending on the duration of utilization of prophylactic antibiotics ( Table 2 ). Four of the 10 studies reported significantly lower SSI rates with prolonged utilization of antibiotics, all of which were subject to bias. Edwards et al. reported lower risk of SSI in women undergoing mastectomy without reconstruction who were given prolonged antibiotics after operation [16] . This study is likely subject to confounding bias as procedures were performed by only two surgeons, with one utilizing preoperative antibiotics and the other continuing antibiotics post-discharge until drains were removed. In three studies, high SSI rates prompted a change in the antibiotic prophylaxis protocol, prolonging the duration of antibiotic administration [64, 91, 102] . In these three studies, the SSI rate in the earlier time period was very high, and the lower SSI rate after the change in antibiotic protocol is consistent with "regression to the mean," in which an extreme rate in one period is likely to move back to the normal rate in a subsequent period in the absence of any intervention [103] . In contrast, no difference in SSI rates in patients undergoing mastectomy and/or breast reconstruction depending on the duration of antibiotic prophylaxis was found in the remaining six studies in Table 2 , although none had sufficient power to detect a difference unless it was relatively large (more than a twofold decrease in SSI rates). We recently analyzed post-discharge antibiotic utilization in a large cohort of over 12,000 women who underwent mastectomy with or without immediate breast reconstruction using private insurer claims data (Olsen et al., unpublished observations) . In procedures with no evidence for complication during the surgical admission, prescription claims for antibiotics within 5 days after hospital discharge were identified after 56% of mastectomy with reconstruction and 23% without immediate reconstruction. Three-quarters of the women prescribed antibiotics in the immediate post-discharge time period were given a cephalosporin. There was no difference in the incidence of SSI in women given post-discharge antibiotics compared to those without antibiotics after mastectomy (p = 0.18) or after immediate reconstruction (p = 0.20), despite having 980% power to detect a difference in SSI rates if a difference existed.
Phillips recently reviewed SSI rates after reconstruction procedures in which prophylactic antibiotics were given for 24 h or less versus more than 24 h, including most of the studies in Table 2 , and found no difference in the summary SSI rates depending on duration of prophylaxis [101••] . Thus, at present, there is no evidence in the literature to support continuation of prophylactic antibiotics beyond 24 h after surgery. There is the potential for harm, however, due to increased risk of infection with Clostridium difficile, development of antibiotic-resistant organisms, and other drug-related complications, including allergic reactions. Consistent with these accepted risks, Throckmorton and colleagues found increased drug-related complication rates in breast or axillary surgical patients given postoperative prophylactic antibiotics compared to only a single pre-incision dose of antibiotics [109] .
Other SSI prevention strategies
In addition to post-discharge prophylactic antibiotic use, a number of other preventive strategies are used by surgeons to reduce the risk of SSI after reconstructive surgery, including preoperative decolonization, preoperative bathing with chlorhexidine solution, irrigation of the mastectomy pocket with an antibiotic-containing solution, soaking the breast implant Power to detect a 50% reduction in observed SSI rates, based on the observed rate with shorter duration of prophylaxis (α = 0.05)
in an antibiotic-containing solution, and perioperative glucose control [110••] . Although decolonization to prevent SSI caused by S. aureus has been studied extensively in other operations, only one group analyzed nasopharyngeal colonization in patients undergoing tissue expander reconstruction. Nishibayashi found significantly increased risk of SSI in women colonized with MRSA compared to uncolonized women, suggesting that decolonization with mupirocin may have benefit in this population [111] . In a recent survey of 253 plastic surgeons performing breast implant surgery (80% in private practice), an antiseptic or antibiotic-containing solution was used by 81% for irrigation and by 86% to soak breast implants prior to implantation [112] . In this survey, the most common choices of irrigant were a triple antibiotic solution, followed by povidone-iodine. Similarly, Viola and colleagues found use of triple antibiotic solution for pocket irrigation in more than 85% of tissue expander reconstructions in 3082 patients over a 10-year period at their institution [44••] . Although use of antiseptic or antibioticcontaining solutions for pocket irrigation and soaking breast implants has been recommended in a guideline from the UK [113] to prevent infection and capsular contracture, thought to be caused by subclinical infection, the evidence to support this practice is weak. Only one prior study found decreased incidence of SSI associated with cephalothin-containing irrigant compared to saline alone in women undergoing cosmetic augmentation [114] . This study used a beforeafter design with over 3 years separating the two time periods studied, and an unusually high SSI rate in the second period when only saline irrigant was used.
Despite this lack of data, use of antiseptic or antibiotic-containing solutions for irrigation and implant soaking is routinely advocated in reviews describing strategies to reduce infection risk in breast implant reconstruction [113, 115, 116] . Khansa and colleagues included irrigation and soaking of implants in a triple antibiotic solution in a standardized protocol to minimize infection risk in tissue expander reconstruction [66] . The protocol also included chlorhexidine bathing the day before and morning of surgery, surgical site antisepsis with chlorhexidine, and prescription of oral antibiotics for prophylaxis postdischarge until drains were removed. They reported a significantly lower SSI rate in the 2-year time period after implementation of the standardized protocol compared to the prior period, although no information was supplied about the prior practices. Optimally, randomized controlled trials to determine the benefit of specific practices, such as antibiotic implant soaking, should be conducted. As this is unlikely, additional studies of standardized infection control interventions are needed to identify specific practices associated with decreased risk of SSI in the breast reconstruction population.
Conclusions
It is clear from a review of the literature that larger multicenter studies are needed to quantify the risk of SSI depending on the type of reconstruction and other operative factors (e.g., ADM, tissue expander versus direct-to-implant, flap type). More data on the baseline risk of SSI after mastectomy without reconstruction are also needed to put the SSI rates associated with breast reconstruction into context. The microbiology of breast SSIs, particularly infections associated with breast implant reconstruction, also requires further research, including study of the local skin microbiome and the origin of Gram-negative bacilli and other unusual flora in these infections. It is important to learn more about the risk of SSI and develop better preventive strategies to lower rates of infection in this vulnerable population of women diagnosed with breast cancer.
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